Drug Profile
Autologous anti-CD19 CAR T-cell therapy - TC BioPharm
Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator TC BioPharm
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for research development in Cancer in United Kingdom (Parenteral)
- 24 Jan 2019 TC BioPharm has patent pending for ImmuniCAR® technology worldwide
- 07 Feb 2018 TC BioPharm and NIPRO Corporation agree to co-develop, sell and distribute anti-CD19 chimeric antigen receptor T-cell therapy